Abstract:Abstract Mutant BRAF, one of the most frequently mutated serine/threonine kinase, drives tumorigenesis via activating MAPK signaling across various tumor types. Expanded genomic and mechanistic studies over the past two decades have revealed the heterogeneity regarding BRAF mutation status and characterized a classification system for BRAF mutations based on their mode of action. Class I (V600 mutants) and class II (K601 mutants, G469A/V/R, etc) BRAF mutants function as RAS-independent active monomers or dimers to amplify MAPK signaling, whereas class III (G466 mutants, D594 mutants, G469E, etc) mutants, which are kinase impaired or dead, promote MAPK signaling via enhanced RAS binding and subsequent CRAF activation. To date, combination therapies of BRAF and MEK inhibitors have been approved for treatment of patients harboring class I BRAF mutations, while viable therapeutic options for those with class II and III BRAF mutations are still ambiguous. Therefore, developing new drugs and personalized therapeutic strategies directing different classes of BRAF mutations, especially class II and III subtypes, have become vital in the war against BRAF-mutant tumors. To enable BRAF-targeted drug discovery and precision medicine, we developed a tailored platform based on the classification of BRAF mutations, which integrates whole exome sequencing (WES) for identification of mutant BRAF subtypes with in vivo efficacy evaluation in patient-derived tumor xenograft (PDX) models. Our platform covers all three classes of BRAF mutants, such as V600E/G469A/D594N/G469E. Moreover, this platform faithfully recapitulate the responses of multiple targeted therapies, such as BRAF, MEK and EGFR inhibitors, reported for treating BRAF-mutant tumors in preclinical and clinical studies, highlighting the potential translation values. Taken together, the platform reported in this study empowers the discovery of novel BRAF inhibitors that can be translated into clinical trials and provides personalized therapeutic options for patients who have poorly responded to standard clinical therapies. Citation Format: Hui Qi, Fuyang Wang, Bingrui Han, Xiaomin Wang, Xiangnan Qiang, Zhixiang Zhang, Qingyang Gu. A tailored platform enables BRAF-targeted drug discovery and precision medicine. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4988.

A Patent Review of BRAF Inhibitors: 2013-2018

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

A patent review of RAF kinase inhibitors (2010-2018).

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity.

A Patent Review of RAF Kinase Inhibitors (2010–2018)

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022

A FGFR1 inhibitor patent review: progress since 2010

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Targeting the multifaceted BRAF in cancer: New directions

Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold As Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies

Design, Synthesis, and Biological Evaluation of New B-RafV600E Kinase Inhibitors

Pathways and targeting avenues of BRAF in non-small cell lung cancer

FAK inhibitors in cancer, a patent review - an update on progress.

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors

Abstract 4988: A tailored platform enables BRAF-targeted drug discovery and precision medicine

Patent Review of Manufacturing Routes to Recently Approved Oncology Drugs: Ibrutinib, Cobimetinib, and Alectinib

Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review

BRAF, a target in melanoma